← Leaderboards
Lawrence Joseph Wheat
Indiana Univ-Purdue Univ At Indianapolis
$1,178,559
Attributed
$1,178,559
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2017–22$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,178,559 · 9
By mechanism
R43$1,178,559 · 2
M01$0 · 7
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- L Joseph Wheat$0
- Mitchell J Goldman$3,011,275
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchAids TherapyHuman Therapy EvaluationHiv InfectionsAntiaids AgentVirus RnaCombination ChemotherapyHuman Immunodeficiency Virus 1AreaAntigensCoccidioidomycosisFungusDiagnosticDiagnosisDiagnostic TestsCostCoccidioides PosadasiiClinical Trial Phase ICoccidioides ImmitisAntibodiesCoccidioidesDetectionEpitopes
Grant awards (53)
Development of Coccidioides Cytokine Release Assay$297,717
R43 · FY2022 · AI · contact PI
Development of Coccidioides Cytokine Release Assay$298,530
R43 · FY2021 · AI · contact PI
Improved Method for the Rapid Diagnosis of Coccidioidomycosis$282,312
R43 · FY2018 · AI · contact PI
Improved Method for the Rapid Diagnosis of Coccidioidomycosis$300,000
R43 · FY2017 · AI · contact PI
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2002 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2002 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2002 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2002 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2002 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2002 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2001 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2001 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2001 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2001 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2001 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2001 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
ADEFOVIR DIPIVOXIL WITH ANTIRETROVIRAL THERAPY IN HIV$0
M01 · FY2000 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2000 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2000 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2000 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2000 · RR
IMMUNOLOGIC AND VIROLOGIC EFFECTS OF PREDNISON ON HIV$0
M01 · FY2000 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2000 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
EFAVIRENZ PLUS REVERSE TRANSCRIPTASE INHIBITORS IN HIV$0
M01 · FY2000 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2000 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2000 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2000 · RR
HEPATITIS C INFECTION AND HIV INFECTION W/ AIDS THERAPY$0
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS$0
M01 · FY2000 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2000 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2000 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2000 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2000 · RR
FTC VS LAMIVUDINE IN HIV INFECTION$0
M01 · FY2000 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ABT 378/RITONAVIR PLUS STAVUDINE AND LAMIVUDINE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR